Literature DB >> 27239368

Association Analysis of NALCN Polymorphisms rs1338041 and rs61973742 in a Chinese Population with Isolated Cervical Dystonia.

Qingqing Zhou1, Jing Yang1, Bei Cao1, Yongping Chen1, Qianqian Wei1, Ruwei Ou1, Wei Song1, Bi Zhao1, Ying Wu1, Huifang Shang1.   

Abstract

Background. A genome-wide association study (GWAS) demonstrated a possible association between cervical dystonia (CD) and a sodium leak channel, nonselective (NALCN) gene. However, the association between NALCN and CD was largely unknown in Asian population. The present study was carried out to examine the associations between the two single nucleotide polymorphisms (SNPs) rs1338041 and rs61973742 in the NALCN gene and CD in a Chinese population. Methods. In a cohort of 201 patients with isolated CD, we genotyped the two SNPs rs1338041 and rs61973742 using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). We also included 289 unrelated, age- and sex-matched healthy controls (HCs) from the same region. Result. No significant differences were observed in either the genotype distributions or the minor allele frequencies (MAFs) of the two SNPs between the CD patients and the HCs. There were no significant differences between early-onset and late-onset CD patients, between patients with and without a positive family history of dystonia, or between patients with and without tremor or sensory tricks. Conclusion. Lack of association between the SNPs of NALCN and CD suggests that the SNPs of NALCN do not play a role in CD in a Chinese population.

Entities:  

Year:  2016        PMID: 27239368      PMCID: PMC4864546          DOI: 10.1155/2016/9281790

Source DB:  PubMed          Journal:  Parkinsons Dis        ISSN: 2042-0080


1. Introduction

Dystonia is a movement disorder characterized by involuntary sustained or intermittent muscle contractions affecting one or more sites of the body causing abnormal, often repetitive movements, postures, or both [1]. Cervical dystonia (CD), the most common form of late-onset focal dystonia, is characterized by sustained or intermittent neck muscle contractions causing abnormal head movements and postures [2, 3]. Up to now, more than 20 loci (from DYT1 to DYT25) have been identified to be the causative loci of primary dystonia [4] after the first identified TOR1A (DYT1) gene linked to early-onset primary dystonia [5, 6]. Among them, CIZ1 (Cip1-interacting zinc finger protein; DYT23), ANO3 (anoctamin 3; DYT24), and GNAL (guanine nucleotide binding protein, alpha activating activity polypeptide, olfactory type; DYT25) genes have been discovered for CD [7-9]. However, mutations of these genes mainly are seen in familial CD patients [4, 10]. Although most of patients with late-onset dystonia often seem to be sporadic patients, it appears to have a strong genetic basis [11]. Unfortunately, at present, the genetic architecture of late-onset dystonia remains largely unknown [10]. A recent genome-wide association study (GWAS) has been performed on British patients with focal CD. In this study, although no loci reached a statistically significant association with CD, the P value of the single nucleotide polymorphism (SNP) rs1338041, which is located in an intron region of sodium leak channel, nonselective (NALCN) gene on chromosome 13, was rather low [12]. After subsequent imputation, the results showed a few clusters with potential significance. Rs61973742 within the 5′ untranslated region (UTR) in the NALCN was one of the most meaningful SNPs [12]. However, a replicated study of the GWAS from Spain found no association between these two SNPs of NALCNrs1338041 and rs61973742—with CD [13]. As we all know, GWAS is an efficient method to understand genetic underpinnings of genetic complicated disease that are not based on prior knowledge; however, false positive results may be produced in the meantime [14]. Therefore, it is necessary to confirm the finding of GWAS in other ethnic groups. In the current study, we investigated the association of the most potential significance SNPs (rs1338041 and rs61973742) of NALCN with CD in a Chinese population.

2. Methods

2.1. Subjects

A total of 201 patients with focal cervical dystonia were recruited from the department of neurology at West China Hospital of Sichuan University. Patients were examined and diagnosed by movement disorder specialists according to the current criteria [15]. Patients carrying GAG deletion mutation of the DYT1 gene and having a known causes, including traumatic or structural brain lesions, or treatment with neuroleptic drugs or patients diagnosed with another syndrome with dystonia, such as Parkinson's disease or dystonia plus syndrome, were excluded from the study. Patients with positive family history of dystonia were defined as having one or more first-degree or second-degree family members with dystonia as previously described [16]. A total of 289 unrelated healthy individuals (59.9% women; mean age 43.35 ± 14.77 years) from the same areas of residence were recruited to the study as the healthy controls (HCs) group. None of the HCs had neurological disorders or psychiatric disorders examined by neurologists. Witten informed consent was obtained from all participants before being enrolled, and the study was approved by the Ethics Committee of Sichuan University.

2.2. Genotyping

Peripheral blood samples were collected from all participants. Genomic DNA was extracted from peripheral blood leukocytes using standard phenol-chloroform procedures. Genotype for rs1338041 and rs61973742 was performed by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) analysis. Two SNPs were all amplified using a forward mismatched primer that creates a restriction enzyme digestion site and the primer sequences and the PCR conditions of two SNPs are shown in Supplementary Table  1, in Supplementary Material available online at http://dx.doi.org/10.1155/2016/9281790. PCR products of the two SNPs were all digested with DraI (New England Biolabs, USA). The RFLP results were confirmed by direct sequencing of the PCR products.

2.3. Statistical Analysis

The genotype and minor allele frequencies (MAFs) between patients and controls were analyzed using a standard chi-square test or Fisher's exact test. The comparison of continuous data was assessed by Student's t-test. The results of all continuous data are presented as the mean ± standard deviation (SD), and a two-tailed P < 0.05 was considered statistically significant. Deviation from Hardy-Weinberg equilibrium (HWE) in controls was tested. Statistical analysis was performed using SPSS version 19.0 (SPSS, Chicago, IL, USA). The power was calculated by the Quanto software (Version 1.2.4; USC, Los Angeles, CA) [13]. The Bonferroni correction for multiple comparisons was performed if necessary.

3. Results

The mean age of 201 patients with CD was 41.25 ± 15.76 years at examination time, and the mean age of onset of patients was 38.27 ± 16.06 years. Among all CD patients, the ratio of male to female was 77/124. Fifty patients (24.9%) had an age of onset less than 26 years, and forty-one patients (20.4%) had a positive family history of dystonia. The genotype frequency distributions in the controls did not deviate significantly from the Hardy-Weinberg equilibrium (0.522 and 0.464 for rs1338041 and rs61973742, resp.). No significant differences were found in the genotype distributions or MAFs of the two SNPs between CD patients and controls (Table 1). No differences were observed in the genotype distributions or MAFs between patients with early-onset and late-onset CD or between patients with and without a family history of dystonia (Table 2). There were no differences in the genotype distributions or MAFs in terms of tremor or sensory tricks (Table 3).
Table 1

Distribution of genotype and allele frequency in cervical dystonia patients and controls.

GenotypeMAF
rs61973742AA (%)AG (%)GG (%) P valueG (%) P valueOR (95% CI)

CD (N = 201)135 (67.2)63 (31.3)3 (1.5)0.18969 (17.2)0.1101.305 (0.941–1.809)
HC (N = 289)177 (61.2)101 (35.0)11 (3.8)0.102# 123 (21.3)0.068# 1.360 (0.978–1.891)#

rs1338041AA (%)AC (%)CC (%) P valueA (%) P valueOR (95% CI)

CD (N = 201)36 (17.9)100 (49.8)65 (32.3)0.145172 (42.8)0.0560.779 (0.603–1.007)
HC (N = 289)72 (24.9)139 (48.1)78 (27.0)0.051# 283 (49.0)0.073# 0.790 (0.611–1.022)#

CD: cervical dystonia; HC: health control; MAF: minor allele frequency; OR: odds ratio; CI: confidence interval.

#Adjusted for sex and age.

Table 2

Distribution of genotype and allele frequency in different clinical feature of cervical dystonia patients.

Variationsrs61973742rs1338041
AA, AG, GG P valueMAF (%) P valueOR (95% CI)AA, AC, CC P valueMAF (%) P valueOR (95% CI)
Sex
 Men (N = 77)49, 26, 20.47630 (19.5)0.3320.771 (0.456–1.304)16, 41, 200.29573 (47.4)0.1401.356 (0.904–2.035)
 Female (N = 124)86, 37, 1 39 (15.7)20, 59, 4599 (39.9)
Family history
 Positive (N = 41)25, 15, 10.59017 (20.7)0.3370.742 (0.403–1.367)6, 18, 170.37030 (36.6)0.2030.723 (0.438–1.193)
 Negative (N = 160)110, 48, 252 (16.3)30, 82, 48142 (44.4)
Age at onset
 <26 (N = 50)37, 11, 20.07715 (15.0)0.5081.234 (0.662–2.300)8, 26, 160.90242 (42.0)0.8540.958 (0.660–1.514)
 >26 (N = 151)98, 52, 154 (17.9)28, 74, 49130 (43.0)

MAF: minor allele frequency; OR: odds ratio; CI: confidence interval.

Table 3

Distribution of genotype and allele frequency in cervical dystonia patients with or without special clinical features.

Variationsrs61973742rs1338041
AA, AG, GG P valueMAF (%) P valueOR (95% CI)AA, AC, CC P valueMAF (%) P valueOR (95% CI)
Sensory trick
 Yes (N = 177)119, 55, 30.80261 (17.2)0.961 (0.428–2.154)33, 86, 580.627152 (42.9)0.8671.053 (0.527–1.941)
 No (N = 24)16, 8, 08 (16.7)0.9223, 14, 720 (41.7)
Tremor
 Yes (N = 108)71, 36, 10.68438 (17.6)0.937 (0.556–1.527)14, 54, 400.09182 (38.0)0.035 0.653 (0.438–0.972)
 No (N = 93)64, 27, 231 (16.7)0.80622, 46, 2590 (48.4)

MAF: minor allele frequency; OR: odds ratio; CI: confidence interval.

No significant differences after the Bonferroni correction.

4. Discussion

This is the first study on the genetic susceptibility of the rs1338041 and rs61973742 SNPs of NALCN and CD in a Chinese population. In the current study, rs1338041 and rs61973742 SNPs were not found to modify the susceptibility to CD. The NALCN gene comprises at least 44 exons (43 coding exons) encoding NALCN, which is a voltage-independent and cation-nonselective channel, and is mainly responsible for the leaky sodium transport across neuronal membranes and controls neuronal excitability [17, 18]. A previous GWAS showed the possible association between the two SNPs of NALCN and CD in 212 British resident CD patients of European descent. Given that ion channels are crucial components of cellular exciting ability and are involved in many neurological diseases, for example, ANO3, whose mutations have detected in sporadic CD, functions as calcium activated chloride channels which modulate neuronal excitability [19]. It supports that an ion channel may be a potential candidate gene for dystonia. Therefore, the British study came to the following conclusion: NALCN, whose encoded protein belongs to a Na+-leak channel, may be a plausible candidate gene for dystonia [12]. However, our current study and the Spanish study both failed to replicate the association of rs1338041 and rs61973742 with CD [12, 13]. Several factors should be considered to explain such difference. First of all, in genetic analysis, ethnic population specificity must be taken into consideration as an essential factor. For example, according to the British GWAS, the minor A-allele of rs1338041 showed a doubtful risk to CD patients for the fact that the frequency of minor A-allele seemed higher in CD patients than controls, while the Spanish population and the present study both manifested a higher frequency of A-allele in controls than in patients, meaning a possible protective effect of A-allele. In the case of rs61973742, this phenomenon does not exist, the potential effects of these three available studies making no difference. Secondly, given that the clinical manifestation of dystonia is diversity, the patients recruited among studies could be different. However, our study is in accordance with previous studies on British or Spanish, both containing focal CD only [12, 13]. Thirdly, a major difference is that the age of onset of CD in our patients (38.27 ± 16.06 years) was much less than the other two studies (British: 60.6 ± 10.9 years, and Spanish: 43.5 ± 15.7 years). Considering this factor, we divided our patients into two groups, early onset and late onset. However, no differences in the genotype or allele frequencies between early-onset and late-onset CD were found either. Therefore, these factors may contribute little to the differences. Finally, the sample size must be taken into consideration. The British GWAS reported a putative association of CD with SNPs in the NALCN. However, there was no single SNP that reached the statistical significance in that no single SNP passed the genome-wide significance level (defined as P < 5 × 10−8) after GWAS. The possible reason is that the sample size is not enough to discover some SNPs with small effect on the disease according to the author. The prevalence of primary dystonia in China was 27.0 per million persons based on the minimum estimates [20]. Therefore, the present study had a probability of 80% power to detect genetic effects at an OR of 1.85 under an additive model in our sample (two-sided, P < 0.01) [13]. The Spanish study also had a strong power to find the association between SNPs of NALCN and CD [13]. To sum up, it seems that variations in the NALCN gene might not be associated with CD. The British GWAS might overvalue the positive effect of SNPs of the NALCN gene in dystonia [12]. In conclusion, the lack of association between NALCN SNPs rs1338041 and rs61973742 and CD suggested that SNPs of the NALCN gene do not play a role in Chinese CD population. The primer sequences, the length of the PCR products and the restriction enzymes used to analyze the SNPs rs1338041 and rs61973742.
  20 in total

Review 1.  The NALCN ion channel is a new actor in pancreatic β-cell physiology.

Authors:  Leigh Anne Swayne; Alexandre Mezghrani; Philippe Lory; Joel Nargeot; Arnaud Monteil
Journal:  Islets       Date:  2010 Jan-Feb       Impact factor: 2.694

2.  How to interpret a genome-wide association study.

Authors:  Thomas A Pearson; Teri A Manolio
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

Review 3.  Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis.

Authors:  Julie Phukan; Alberto Albanese; Thomas Gasser; Thomas Warner
Journal:  Lancet Neurol       Date:  2011-10-24       Impact factor: 44.182

4.  Mutations in NALCN cause an autosomal-recessive syndrome with severe hypotonia, speech impairment, and cognitive delay.

Authors:  Moeenaldeen D Al-Sayed; Hamad Al-Zaidan; Albandary Albakheet; Hana Hakami; Rosan Kenana; Yusra Al-Yafee; Mazhor Al-Dosary; Alya Qari; Tarfa Al-Sheddi; Muhammed Al-Muheiza; Wafa Al-Qubbaj; Yamina Lakmache; Hindi Al-Hindi; Muhammad Ghaziuddin; Dilek Colak; Namik Kaya
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

Review 5.  Recent developments in dystonia.

Authors:  Hyder A Jinnah; Jan K Teller; Wendy R Galpern
Journal:  Curr Opin Neurol       Date:  2015-08       Impact factor: 5.710

6.  The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein.

Authors:  L J Ozelius; J W Hewett; C E Page; S B Bressman; P L Kramer; C Shalish; D de Leon; M F Brin; D Raymond; D P Corey; S Fahn; N J Risch; A J Buckler; J F Gusella; X O Breakefield
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

Review 7.  Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment.

Authors:  Carlos Henrique Ferreira Camargo; Lígia Cattai; Hélio Afonso Ghizoni Teive
Journal:  Toxins (Basel)       Date:  2015-06-23       Impact factor: 4.546

8.  Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis.

Authors:  Gavin Charlesworth; Vincent Plagnol; Kira M Holmström; Jose Bras; Una-Marie Sheerin; Elisavet Preza; Ignacio Rubio-Agusti; Mina Ryten; Susanne A Schneider; Maria Stamelou; Daniah Trabzuni; Andrey Y Abramov; Kailash P Bhatia; Nicholas W Wood
Journal:  Am J Hum Genet       Date:  2012-11-29       Impact factor: 11.025

Review 9.  Cervical dystonia: a disorder of the midbrain network for covert attentional orienting.

Authors:  Michael Hutchinson; Tadashi Isa; Anna Molloy; Okka Kimmich; Laura Williams; Fiona Molloy; Helena Moore; Daniel G Healy; Tim Lynch; Cathal Walsh; John Butler; Richard B Reilly; Richard Walsh; Sean O'Riordan
Journal:  Front Neurol       Date:  2014-04-28       Impact factor: 4.003

10.  Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel.

Authors:  Kin Y Mok; Susanne A Schneider; Daniah Trabzuni; Maria Stamelou; Mark Edwards; Dalia Kasperaviciute; Stuart Pickering-Brown; Monty Silverdale; John Hardy; Kailash P Bhatia
Journal:  Mov Disord       Date:  2013-11-13       Impact factor: 10.338

View more
  4 in total

Review 1.  [Genetic risk variants in Parkinson's disease and other movement disorders].

Authors:  K Brockmann; K Lohmann
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

2.  Pathogenic convergence of CNVs in genes functionally associated to a severe neuromotor developmental delay syndrome.

Authors:  Juan L García-Hernández; Luis A Corchete; Íñigo Marcos-Alcalde; Paulino Gómez-Puertas; Carmen Fons; Pedro A Lazo
Journal:  Hum Genomics       Date:  2021-02-08       Impact factor: 4.639

Review 3.  Risk Factor Genes in Patients with Dystonia: A Comprehensive Review.

Authors:  Vasileios Siokas; Athina-Maria Aloizou; Zisis Tsouris; Amalia Michalopoulou; Alexios-Fotios A Mentis; Efthimios Dardiotis
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2019-01-09

4.  Association Between Dystonia-Related Genetic Loci and Parkinson's Disease in Eastern China.

Authors:  Wen-Yi Yang; Si-Si Jiang; Jia-Li Pu; Chong-Yao Jin; Ting Gao; Ran Zheng; Jun Tian; Bao-Rong Zhang
Journal:  Front Neurol       Date:  2022-02-22       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.